Key Takeaways
- • Ansa Biotechnologies closed a $71.5 million oversubscribed Series C financing, bringing its total funding to $211 million, according to a Business Wire announcement.
- • Blue Water Life Science Advisors led the round, with new investors Illumina Ventures, BEVC, Lightscape Partners, and Agent Capital, alongside existing investors Cerberus Ventures, Fall Line Capital, Dauntless Ventures, and Altitude Life Science Ventures.
- • The company quadrupled its manufacturing capacity over the past year to meet demand for long, complex synthetic DNA used in AI-enabled drug discovery and biological design.
- • Nick Naclerio, Brad Crutchfield, and Nate Cornell joined the board of directors, with Crutchfield serving as an independent director; Matthew McManus is stepping down.
- • Ansa's On-Time Guarantee commits to a ship date, with the entire order provided free if that date is missed.
Summary
The round was led by Blue Water Life Science Advisors. New investors include Illumina Ventures, BEVC, Lightscape Partners, and Agent Capital, while existing investors Cerberus Ventures, Fall Line Capital, Dauntless Ventures, and Altitude Life Science Ventures also participated. The company described the financing as bringing together leading life science investment firms and strategic investors with deep expertise in the life science tools industry.
The company framed the raise against advances in AI-enabled drug discovery and biological design, which are increasing demand for longer and more complex DNA sequences. Ansa said conventional synthesis is limited by sequence length, complexity, and manufacturing reliability, which can prevent researchers from converting computational designs into physical DNA needed to validate AI models. Its proprietary enzymatic DNA synthesis platform is positioned to address these constraints.
Over the past year, Ansa quadrupled its manufacturing capacity to support applications in drug discovery, cell and gene therapies, vaccines, and agrigenomics. The company offers sequence-perfect clonal DNA up to 50 kilobases and sequence-verified linear double-stranded DNA fragments. CEO Jason T. Gammack said the oversubscribed financing validates the company's commercial success and provides resources to expand capacity and serve more customers.
For governance, Nick Naclerio, founding partner of Illumina Ventures; Brad Crutchfield, a former chief commercial officer at 10x Genomics and president of Bio-Rad's Life Science Group; and Nate Cornell, founder and chief investment officer of Blue Water Life Science Advisors, joined the board. Crutchfield will serve as an independent director, and Rowan Chapman, PhD, co-founder of BEVC, joined as a board observer. Matthew McManus, MD, PhD, is stepping down from the board after three years.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.